Ron Dagan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6648567/publications.pdf

Version: 2024-02-01

259 papers	14,857 citations	12322 69 h-index	24232 110 g-index
266 all docs	266 docs citations	266 times ranked	8173 citing authors

#	Article	IF	Citations
1	Dynamics of Invasive Pneumococcal Disease in Israel in Children and Adults in the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Era: A Nationwide Prospective Surveillance. Clinical Infectious Diseases, 2022, 74, 1639-1649.	2.9	14
2	Effectiveness of BNT162b2 mRNA Coronavirus Disease 2019 (COVID-19) Vaccine Against Acquisition of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Healthcare Workers in Long-Term Care Facilities: A Prospective Cohort Study. Clinical Infectious Diseases, 2022, 75, e755-e763.	2.9	18
3	Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged â‰¥50Âyears: A randomized phase 3 trial (PNEU-TRUE). Vaccine, 2022, 40, 1342-1351.	1.7	5
4	The impact of the pneumococcal conjugate vaccines on the incidence of community-acquired alveolar pneumonia in premature compared with in term-born infants. Vaccine, 2022, 40, 568-573.	1.7	1
5	Effects of BNT162b2 Covid-19 Vaccine Booster in Long-Term Care Facilities in Israel. New England Journal of Medicine, 2022, 386, 399-401.	13.9	31
6	Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. New England Journal of Medicine, 2022, 386, 837-846.	13.9	328
7	A Streptococcus pneumoniae lineage usually associated with pneumococcal conjugate vaccine (PCV) serotypes is the most common cause of serotype 35B invasive disease in South Africa, following routine use of PCV. Microbial Genomics, 2022, 8, .	1.0	4
8	Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18â€“49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY). Open Forum Infectious Diseases, 2022, 9, ofab605.	0.4	9
9	Decline in Pneumococcal Disease in Young Children During the Coronavirus Disease 2019 (COVID-19) Pandemic in Israel Associated With Suppression of Seasonal Respiratory Viruses, Despite Persistent Pneumococcal Carriage: A Prospective Cohort Study. Clinical Infectious Diseases, 2022, 75, e1154-e1164.	2.9	95
10	The Effect of Macrolides on Mortality in Bacteremic Pneumococcal Pneumonia: A Retrospective, Nationwide Cohort Study, Israel, 2009â€“2017. Clinical Infectious Diseases, 2022, 75, 2219-2224.	2.9	4
11	Association of Receipt of the Fourth BNT162b2 Dose With Omicron Infection and COVID-19 Hospitalizations Among Residents of Long-term Care Facilities. JAMA Internal Medicine, 2022, 182, 859.	2.6	40
12	The Pneumococcusâ€“Respiratory Virus Connectionâ€”Unexpected Lessons From the COVID-19 Pandemic. JAMA Network Open, 2022, 5, e2218966.	2.8	8
13	Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19â€“Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021. JAMA Network Open, 2022, 5, e2219940.	2.8	13
14	A Prospective, Population-based Study to Determine the Incidence and Bacteriology of Bacterial Conjunctivitis in Children <2 Years of Age Following 7-Valent and 13-Valent Pneumococcal Conjugate Vaccine Sequential Implementation. Clinical Infectious Diseases, 2021, 72, 1200-1207.	2.9	7
15	Carrier-Induced Hyporesponsiveness to Pneumococcal Conjugate Vaccines: Unraveling the Influence of Serotypes, Timing, and Previous Vaccine Dose. Clinical Infectious Diseases, 2021, 72, 448-454.	2.9	8
16	Serotype Patterns of Pneumococcal Disease in Adults Are Correlated With Carriage Patterns in Older Children. Clinical Infectious Diseases, 2021, 72, e768-e775.	2.9	10
17	TIPICO X: report of the 10th interactive infectious disease workshop on infectious diseases and vaccines. Human Vaccines and Immunotherapeutics, 2021, 17, 759-772.	1.4	1
18	Pneumococcal Vaccines. , 2021, , 223-247.		0

#	Article	IF	Citations
19	Changes in Invasive Pneumococcal Disease Caused by Streptococcus pneumoniae Serotype 1 following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project. Microorganisms, 2021, 9, 696.	1.6	10
20	Serotype Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10/13 Period: Findings from the PSERENADE Project. Microorganisms, 2021, 9, 738.	1.6	31
21	Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project. Microorganisms, 2021, 9, 742.	1.6	30
22	Unraveling the Impact of Pneumococcal Conjugate Vaccines on Ambulatory Antibiotic Drug Consumption in Young Children: An Interrupted Time-Series Analysis. Clinical Infectious Diseases, 2021, 73, 1268-1278.	2.9	10
23	Decline in pneumococcal nasopharyngeal carriage in children 6â€“23Âmonths with respiratory illnesses following pneumococcal conjugate vaccine implementation. Vaccine, 2021, 39, 5757-5761.	1.7	0
24	Effectiveness of the 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-Serotype Otitis Media. Clinical Infectious Diseases, 2021, 73, 650-658.	2.9	13
25	Postâ€“13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children of Serotypes Included in Candidate Extended-Spectrum Conjugate Vaccines. Emerging Infectious Diseases, 2021, 27, 150-160.	2.0	16
26	Effectiveness of Pneumococcal Conjugate Vaccines Against Community-acquired Alveolar Pneumonia Attributable to Vaccine-serotype Streptococcus pneumoniae Among Children. Clinical Infectious Diseases, 2021, 73, e1423-e1433.	2.9	10
27	Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. New England Journal of Medicine, 2021, 385, 2140-2149.	13.9	445
28	Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged â‰¥50 years: a randomized phase 3 trial (PNEU-FLU). Human Vaccines and Immunotherapeutics, 2021, , 1-14.	1.4	10
29	Use of Chest Radiography Examination as a Probe for Pneumococcal Conjugate Vaccine Impact on Lower Respiratory Tract Infections in Young Children. Clinical Infectious Diseases, 2020, 71, 177-187.	2.9	19
30	Dose-specific Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-serotype Streptococcus pneumoniae Colonization in Children. Clinical Infectious Diseases, 2020, 71, e289-e300.	2.9	22
31	A Nationwide Outbreak of Invasive Pneumococcal Disease in Israel Caused by Streptococcus Pneumoniae Serotype 2. Clinical Infectious Diseases, 2020, 73, e3768-e3777.	2.9	3
32	Evaluating post-vaccine expansion patterns of pneumococcal serotypes. Vaccine, 2020, 38, 7756-7763.	1.7	13
33	Substantial reduction of antibiotic-non-susceptible pneumococcal otitis media following PCV7/PCV13 sequential introduction. Journal of Antimicrobial Chemotherapy, 2020, 75, 3038-3045.	1.3	6
34	Characterization of children younger than 5ÂYears of age with severe community-acquired alveolar pneumonia (CAAP) requiring Pediatric Intensive Care Unit (PICU) admission. Pediatrics and Neonatology, 2020, 61, 406-413.	0.3	3
35	Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus Statement. Frontiers in Immunology, 2020, 11, 1282.	2.2	68
36	Unique Features of Hospitalized Children with Alveolar Pneumonia Suggest Frequent Viral-Bacterial Coinfections. Pediatric Infectious Disease Journal, 2020, 39, 586-590.	1.1	10

#	Article	IF	Citations
37	Stable dynamics of pneumococcal carriage over a decade in the pre-PCV era. Vaccine, 2019, 37, 5625-5629.	1.7	3
38	Hospital-onset adult invasive pneumococcal disease in Israel: Sicker patients, different pathogens. International Journal of Infectious Diseases, 2019, 85, 195-202.	1.5	4
39	Nasopharyngeal Carriage of Invasive Pneumococcal Serotypes During Childhood Community-Acquired Alveolar Pneumonia Is Associated With Specific Clinical Presentation. Journal of Infectious Diseases, 2019, 221, 812-819.	1.9	3
40	Relationship between immune response to pneumococcal conjugate vaccines in infants and indirect protection after vaccine implementation. Expert Review of Vaccines, 2019, 18, 641-661.	2.0	26
41	Interaction With Nontypeable Haemophilus influenzae Alters Progression of Streptococcus pneumoniae From Colonization to Disease in a Site-Specific Manner. Journal of Infectious Diseases, 2019, 220, 1367-1376.	1.9	6
42	Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study. Lancet Infectious Diseases, The, 2019, 19, 759-769.	4.6	165
43	International genomic definition of pneumococcal lineages, to contextualise disease, antibiotic resistance and vaccine impact. EBioMedicine, 2019, 43, 338-346.	2.7	168
44	Streptococcus pneumoniae Cell Wall-Localized Trigger Factor Elicits a Protective Immune Response and Contributes to Bacterial Adhesion to the Host. Scientific Reports, 2019, 9, 4295.	1.6	8
45	Association Between the Decline in Pneumococcal Disease in Unimmunized Adults and Vaccine-Derived Protection Against Colonization in Toddlers and Preschool-Aged Children. American Journal of Epidemiology, 2019, 188, 160-168.	1.6	45
46	Studying PCV impact on clinical presentation of otitis media helps to understand its pathogenesis. Vaccine, 2019, 37, 1-6.	1.7	8
47	Understanding the Evolution of Antibiotic-nonsusceptible Pneumococcal Nasopharyngeal Colonization Following Pneumococcal Conjugate Vaccine Implementation in Young Children. Clinical Infectious Diseases, 2019, 69, 648-656.	2.9	18
48	Maternal Education Is Inversely Related to Vaccination Delay among Infants and Toddlers. Journal of Pediatrics, 2019, 205, 120-125.e2.	0.9	5
49	Putative novel cps loci in a large global collection of pneumococci. Microbial Genomics, 2019, 5, .	1.0	14
50	A toddler PCV booster dose following 3 infancy priming doses increases circulating serotype-specific IGG levels but does not increase protection against carriage. Vaccine, 2018, 36, 2774-2782.	1.7	3
51	Pneumococcal Phenotype and Interaction with Nontypeable Haemophilus influenzae as Determinants of Otitis Media Progression. Infection and Immunity, 2018, 86, .	1.0	17
52	Serotype-specific immune responses to pneumococcal conjugate vaccine among children are significantly correlated by individual: Analysis of randomized controlled trial data. Vaccine, 2018, 36, 473-478.	1.7	11
53	Flavin Reductase Contributes to Pneumococcal Virulence by Protecting from Oxidative Stress and Mediating Adhesion and Elicits Protection Against Pneumococcal Challenge. Scientific Reports, 2018, 8, 314.	1.6	6
54	Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: Insights from Israeli surveillance studies. Vaccine, 2018, 36, 5477-5484.	1.7	38

#	Article	IF	Citations
55	Nitric oxide inhalations in bronchiolitis: A pilot, randomized, doubleâ€blinded, controlled trial. Pediatric Pulmonology, 2018, 53, 95-102.	1.0	13
56	1431. Dynamics of Antibiotic Prescription Rate Following Pneumococcal Conjugate Vaccine (PCV) Implementation in Children <2 Years Old: Comparison Between High and Low Prescribing Clinics in Two Different Ethnic Groups. Open Forum Infectious Diseases, 2018, 5, S442-S442.	0.4	0
57	1433. Association Between Impact of Pneumococcal Conjugate Vaccines (PCVs) on Acute Respiratory Infections Rates and Impact on Antibiotic Consumption Rates in Young Children. Open Forum Infectious Diseases, 2018, 5, S443-S443.	0.4	0
58	First Otitis Media and Pneumococcal Conjugate Vaccine Serotypes in Infants. Pediatric Infectious Disease Journal, 2018, 37, e351-e352.	1.1	1
59	Emergence ofStreptococcus pneumoniaeSerotype 12F after Sequential Introduction of 7- and 13-Valent Vaccines, Israel. Emerging Infectious Diseases, 2018, 24, 453-461.	2.0	43
60	On King Saul, Two Missing Mules, and Kingella kingae: The Serendipitous Discovery of a Pediatric Pathogen. Pediatric Infectious Disease Journal, 2018, 37, 1264-1266.	1.1	1
61	Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines. , 2018, , 773-815.e18.		9
62	The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: A systematic review and meta-analysis. Journal of Infection, 2018, 77, 368-378.	1.7	100
63	Dynamics of Severe and Non-severe Invasive Pneumococcal Disease in Young Children in Israel Following PCV7/PCV13 Introduction. Pediatric Infectious Disease Journal, 2018, 37, 1048-1053.	1.1	15
64	Pneumococcal Meningitis in Adults after Introduction of PCV7 and PCV13, Israel, July 2009â€“June 20151. Emerging Infectious Diseases, 2018, 24, 1275-1284.	2.0	18
65	Impact of pneumococcal conjugate vaccines introduction on antibiotic resistance of Streptococcus pneumoniae meningitis in children aged 5 years or younger, Israel, 2004 to 2016. Eurosurveillance, 2018, 23, .	3.9	9
66	Nasopharyngeal pneumococcal carriage during childhood community-acquired alveolar pneumonia: Relationship between specific serotypes and co-infecting viruses. Journal of Infectious Diseases, 2017, 215, jiw613.	1.9	25
67	PCV13-vaccinated children still carrying PCV13 additional serotypes show similar carriage density to a control group of PCV7-vaccinated children. Vaccine, 2017, 35, 945-950.	1.7	16
68	The herd effects of infant PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel. Vaccine, 2017, 35, 2449-2456.	1.7	41
69	Adhesion and invasion of Streptococcus pneumoniae to primary and secondary respiratory epithelial cells. Molecular Medicine Reports, 2017, 15, 65-74.	1.1	36
70	Cocontribution of Rotavirus and Pneumococcal Conjugate Vaccines to the Reduction of Pediatric Hospital Visits in Young Children. Journal of Pediatrics, 2017, 182, 253-259.e2.	0.9	10
71	Invasive pneumococcal disease (IPD) in HIV infected patients in Israel since the introduction of pneumococcal conjugated vaccines (PCV): Analysis of a nationwide surveillance study, 2009â€“2014. Human Vaccines and Immunotherapeutics, 2017, 13, 216-219.	1.4	5
72	Pan-serotype Reduction in Progression of Streptococcus pneumoniae to Otitis Media After Rollout of Pneumococcal Conjugate Vaccines. Clinical Infectious Diseases, 2017, 65, 1853-1861.	2.9	23

#	Article	IF	Citations
73	Antibiotic Prescription Rates in Children <24 Months Old Following PCV7/PCV13 Sequential Implementation. Open Forum Infectious Diseases, 2017, 4, S465-S466.	0.4	1
74	Pneumococcal Vaccines. , 2017, , 197-213.		1
75	Long-term Serologic Follow-up of Children Vaccinated with a Pediatric Formulation of Virosomal Hepatitis A Vaccine Administered With Routine Childhood Vaccines at 12â€“15 Months of Age. Pediatric Infectious Disease Journal, 2016, 35, e220-e228.	1.1	11
76	The 25th European Congress of clinical microbiology and infectious diseases (ECCMID) in Copenhagen, Denmark. Human Vaccines and Immunotherapeutics, 2016, 12, 749-750.	1.4	0
77	Surveillance of pneumococcal diseases in Central and Eastern Europe. Human Vaccines and Immunotherapeutics, 2016, 12, 2124-2134.	1.4	20
78	Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid). Human Vaccines and Immunotherapeutics, 2016, 12, 1-18.	1.4	49
79	The impact of pneumococcal conjugate vaccines on carriage of and disease caused by Streptococcus pneumoniae serotypes 6C and 6D in southern Israel. Vaccine, 2016, 34, 2806-2812.	1.7	13
80	Modeling pneumococcal nasopharyngeal acquisition as a function of anticapsular serum antibody concentrations after pneumococcal conjugate vaccine administration. Vaccine, 2016, 34, 4313-4320.	1.7	33
81	Disparities in PCV impact between different ethnic populations cohabiting in the same region: A systematic review of the literature. Vaccine, 2016, 34, 4371-4377.	1.7	15
82	Density, Serotype Diversity, and Fitness ofStreptococcus pneumoniaein Upper Respiratory Tract Cocolonization With NontypeableHaemophilus influenzae. Journal of Infectious Diseases, 2016, 214, 1411-1420.	1.9	25
83	Using Pneumococcal Carriage Data to Monitor Postvaccination Changes in the Incidence of Pneumococcal Otitis Media. American Journal of Epidemiology, 2016, 184, 652-659.	1.6	17
84	Estimation and Interpretation of Heterogeneous Vaccine Efficacy Against Recurrent Infections. Biometrics, 2016, 72, 976-985.	0.8	10
85	Real-World Effectiveness of Pentavalent Rotavirus Vaccine Among Bedouin and Jewish Children in Southern Israel. Clinical Infectious Diseases, 2016, 62, S155-S160.	2.9	21
86	Impact of Widespread Introduction of Pneumococcal Conjugate Vaccines on Pneumococcal and Nonpneumococcal Otitis Media. Clinical Infectious Diseases, 2016, 63, 611-618.	2.9	86
87	Pneumococcal nasopharyngeal carriage in children <5Â years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel. Human Vaccines and Immunotherapeutics, 2016, 12, 268-276.	1.4	60
88	Epidemiological Markers for Interactions AmongStreptococcus pneumoniae,Haemophilus influenzae, andStaphylococcus aureusin Upper Respiratory Tract Carriage. Journal of Infectious Diseases, 2016, 213, 1596-1605.	1.9	49
89	Prevention of early episodes of otitis media by pneumococcal vaccines might reduce progression to complex disease. Lancet Infectious Diseases, The, 2016, 16, 480-492.	4.6	114
90	The diversity of pneumococcal conjugate vaccine impact observed through their implementation. Human Vaccines and Immunotherapeutics, 2016, 12, 266-267.	1.4	2

#	Article	IF	Citations
91	Streptococcus pneumoniae Cell-Wall-Localized Phosphoenolpyruvate Protein Phosphotransferase Can Function as an Adhesin: Identification of Its Host Target Molecules and Evaluation of Its Potential as a Vaccine. PLoS ONE, 2016, 11, e0150320.	1.1	22
92	Streptococcus pneumoniae serotype 6C in Costa Rican children with otitis media before introduction of the 7-valent pneumococcal conjugated vaccine into the national immunization program. Journal of Pediatric Infectious Diseases, 2015, 06, 243-246.	0.1	0
93	Seasonality of Both Bacteremic and Nonbacteremic Pneumonia Coincides With Viral Lower Respiratory Tract Infections in Early Childhood, in Contrast to Nonpneumonia Invasive Pneumococcal Disease, in the Pre-Pneumococcal Conjugate Vaccine Era. Clinical Infectious Diseases, 2015, 60, 1384-1387.	2.9	33
94	Early impact of PCV7/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: A nationwide surveillance study. Vaccine, 2015, 33, 1135-1142.	1.7	55
95	Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years. Vaccine, 2015, 33, 4623-4629.	1.7	88
96	Rapid impact of rotavirus vaccine introduction to the National Immunization Plan in Southern Israel: Comparison between 2 distinct populations. Vaccine, 2015, 33, 1934-1940.	1.7	22
97	Differential Impact of Pneumococcal Conjugate Vaccines on Bacteremic Pneumonia Versus Other Invasive Pneumococcal Disease. Pediatric Infectious Disease Journal, 2015, 34, 409-416.	1.1	22
98	Efficacy of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus That of 7-Valent PCV (PCV7) Against Nasopharyngeal Colonization of Antibiotic-NonsusceptibleStreptococcus pneumoniae. Journal of Infectious Diseases, 2015, 211, 1144-1153.	1.9	66
99	Primary School Children Constitute an Important Pneumococcal Vaccine Serotype (VT) Reservoir, 5 Years After Initiation of Widespread Pneumococcal Conjugate Vaccine (PCV) Program. Open Forum Infectious Diseases, 2015, 2, .	0.4	1
100	Changing the Ecology of Pneumococci with Antibiotics and Vaccines. , 2014, , 281-313.		6
101	653Implementation of PCV7/PCV13 in Israel Had a Significant Impact on both Pneumococcal and Non-Pneumococcal Complex Otitis Media (OM) Rates. Open Forum Infectious Diseases, 2014, 1, S182-S183.	0.4	3
102	Timing of bacterial carriage sampling in vaccine trials: A modelling study. Epidemics, 2014, 9, 8-17.	1.5	12
103	Post HocAnalysis of a Randomized Double-Blind Trial of the Correlation of Functional and Binding Antibody Responses Elicited by 13-Valent and 7-Valent Pneumococcal Conjugate Vaccines and Association with Nasopharyngeal Colonization. Vaccine Journal, 2014, 21, 1277-1281.	3.2	25
104	Age-Dependent Carriage of Kingella kingae in Young Children and Turnover of Colonizing Strains. Journal of the Pediatric Infectious Diseases Society, 2014, 3, 160-162.	0.6	37
105	Near-Elimination of Otitis Media Caused by 13-Valent Pneumococcal Conjugate Vaccine (PCV) Serotypes in Southern Israel Shortly After Sequential Introduction of 7-Valent/13-Valent PCV. Clinical Infectious Diseases, 2014, 59, 1724-1732.	2.9	149
106	Short-course Antibiotic Treatment for Community-acquired Alveolar Pneumonia in Ambulatory Children. Pediatric Infectious Disease Journal, 2014, 33, 136-142.	1.1	87
107	Increased Risk for Respiratory Syncytial Virus-associated, Community-acquired Alveolar Pneumonia in Infants Born at 31â€“36 Weeks of Gestation. Pediatric Infectious Disease Journal, 2014, 33, 381-386.	1.1	20
108	Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: An active prospective nationwide surveillance. Vaccine, 2014, 32, 3452-3459.	1.7	116

#	Article	IF	Citations
109	Acute mastoiditis in children under 15 years of age in Southern Israel following the introduction of pneumococcal conjugate vaccines: A 4-year retrospective study (2009â€“2012). International Journal of Pediatric Otorhinolaryngology, 2014, 78, 1599-1604.	0.4	23
110	Evolving Role of 13-valent Pneumococcal Conjugate Vaccine in Clinical Practice. Pediatric Infectious Disease Journal, 2014, 33, 858-864.	1.1	17
111	Initial Effects of the National PCV7 Childhood Immunization Program on Adult Invasive Pneumococcal Disease in Israel. PLoS ONE, 2014, 9, e88406.	1.1	10
112	Comparative Immunogenicity and Efficacy of 13-Valent and 7-Valent Pneumococcal Conjugate Vaccines in Reducing Nasopharyngeal Colonization: A Randomized Double-Blind Trial. Clinical Infectious Diseases, 2013, 57, 952-962.	2.9	192
113	Pneumococcal conjugate vaccine and pneumococcal common protein vaccines. , 2013, , 504-541.		10
114	A nationwide surveillance of invasive pneumococcal disease in adults in Israel before an expected effect of PCV7. Vaccine, 2013, 31, 2387-2394.	1.7	12
115	The relationship between pneumococcal serotypes and antibiotic resistance. Pediatria Polska, 2013, 88, T25-T37.	0.1	1
116	Influence of Pneumococcal Vaccines and Respiratory Syncytial Virus on Alveolar Pneumonia, Israel. Emerging Infectious Diseases, 2013, 19, 1084-1091.	2.0	34
117	Mixed Pneumococcalâ€“Nontypeable Haemophilus influenzae Otitis Media Is a Distinct Clinical Entity With Unique Epidemiologic Characteristics and Pneumococcal Serotype Distribution. Journal of Infectious Diseases, 2013, 208, 1152-1160.	1.9	43
118	Baseline Epidemiology and Genetic Structure of Streptococcus pneumoniae Serotype 6D in Southern Israel Prior to Introduction of Pneumococcal Conjugate Vaccines. Journal of Clinical Microbiology, 2013, 51, 1580-1582.	1.8	4
119	Serotype Childhood Invasive Pneumococcal Disease has Unique Characteristics Compared to Disease Caused by Other Streptococcus pneumoniae Serotypes. Pediatric Infectious Disease Journal, 2013, 32, 614-618.	1.1	11
120	NADH Oxidase Functions as an Adhesin in Streptococcus pneumoniae and Elicits a Protective Immune Response in Mice. PLoS ONE, 2013, 8, e61128.	1.1	23
121	Serum IgM Antibodies Contribute to High Levels of Opsonophagocytic Activities in Toddlers Immunized with a Single Dose of the 9-Valent Pneumococcal Conjugate Vaccine. Vaccine Journal, 2012, 19, 1618-1623.	3.2	29
122	Association of Serotype-Specific Antibody Concentrations and Functional Antibody Titers with Subsequent Pneumococcal Carriage in Toddlers Immunized with a 9-Valent Pneumococcal Conjugate Vaccine. Vaccine Journal, 2012, 19, 96-99.	3.2	10
123	Clonal Distribution of Common Pneumococcal Serotypes Not Included in the 7-Valent Conjugate Vaccine (PCV7): Marked Differences between Two Ethnic Populations in Southern Israel. Journal of Clinical Microbiology, 2012, 50, 3472-3477.	1.8	15
124	Sleep-Disordered Breathing Is a Risk Factor for Community-Acquired Alveolar Pneumonia in Early Childhood. Chest, 2012, 141, 1210-1215.	0.4	22
125	The fundamental link between pneumococcal carriage and disease. Expert Review of Vaccines, 2012, 11, 841-855.	2.0	519
126	Prospective epidemiologic surveillance of invasive pneumococcal disease and pneumonia in children in San JosÃ©, Costa Rica. Vaccine, 2012, 30, 2342-2348.	1.7	12

#	Article	IF	Citations
127	The relationship between pneumococcal serotypes and antibiotic resistance. Vaccine, 2012, 30, 2728-2737.	1.7	115
128	Streptococcus pneumoniae serotypes isolated from the middle ear fluid of Costa Rican children following introduction of the heptavalent pneumococcal conjugate vaccine into a limited population. Vaccine, 2012, 30, 3857-3861.	1.7	5
129	The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: A randomized controlled trial. Vaccine, 2012, 30, 5132-5140.	1.7	51
130	Prevention of pneumococcal diseases in the post-seven valent vaccine era: A European perspective. BMC Infectious Diseases, 2012, 12, 207.	1.3	121
131	Respiratory viral and pneumococcal coinfection of the respiratory tract: implications of pneumococcal vaccination. Expert Review of Respiratory Medicine, 2012, 6, 451-465.	1.0	21
132	Dynamics of Pneumococcal Acquisition and Carriage in Young Adults during Training in Confined Settings in Israel. PLoS ONE, 2012, 7, e46491.	1.1	14
133	Distribution, dynamics and antibiotic resistance patterns of Streptococcus pneumoniae serotypes causing acute otitis media in children in southern Israel during the 10 year-period before the introduction of the 7-valent pneumococcal conjugate vaccine. Vaccine, 2011, 29, 4202-4209.	1.7	25
134	Immunogenicity of pneumococcal conjugate vaccines in infants after two or three primary vaccinations: A systematic review and meta-analysis. Vaccine, 2011, 29, 9600-9606.	1.7	27
135	Nasopharyngeal Carriage of Individual Streptococcus pneumoniae Serotypes During Pediatric Pneumonia as a Means to Estimate Serotype Disease Potential. Pediatric Infectious Disease Journal, 2011, 30, 227-233.	1.1	81
136	The Remaining Challenge of Pneumonia. Pediatric Infectious Disease Journal, 2011, 30, 1-2.	1.1	145
137	Reduction in Antibiotic Use Following a Cluster Randomized Controlled Multifaceted Intervention: The Israeli Judicious Antibiotic Prescription Study. Clinical Infectious Diseases, 2011, 53, 33-41.	2.9	67
138	Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules. Expert Review of Vaccines, 2011, 10, 1621-1631.	2.0	50
139	Immunogenicity of Alternative Regimens of the Conjugated 7-Valent Pneumococcal Vaccine. Pediatric Infectious Disease Journal, 2010, 29, 756-762.	1.1	50
140	Increasing Importance of Multidrug-Resistant Serotype 6A Streptococcus pneumoniae Clones in Acute Otitis Media in Southern Israel. Pediatric Infectious Disease Journal, 2010, 29, 126-130.	1.1	25
141	Association of Human Metapneumovirus with Radiologically Diagnosed Community-Acquired Alveolar Pneumonia in Young Children. Journal of Pediatrics, 2010, 156, 115-120.	0.9	73
142	What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of Streptococcus pneumoniae ?. Journal of the Royal Society Interface, 2010, 7, 905-919.	1.5	83
143	Differential Circulation of Streptococcus pneumoniae Serotype 6C Clones in Two Israeli Pediatric Populations. Journal of Clinical Microbiology, 2010, 48, 4649-4651.	1.8	9
144	Nasopharyngeal Carriage ofStreptococcus pneumoniaeShortly before Vaccination with a Pneumococcal Conjugate Vaccine Causes Serotypeâ€Specific Hyporesponsiveness in Early Infancy. Journal of Infectious Diseases, 2010, 201, 1570-1579.	1.9	93

#	Article	IF	Citations
145	Association of Serotype with Risk of Death Due to Pneumococcal Pneumonia: A Metaâ€Analysis. Clinical Infectious Diseases, 2010, 51, 692-699.	2.9	297
146	Marking November 12, 2010 – World Pneumonia Day: Where are we, where are vaccines?. Hum Vaccin, 2010, 6, 922-925.	2.4	5
147	Glycoconjugate vaccines and immune interference: A review. Vaccine, 2010, 28, 5513-5523.	1.7	216
148	Control of Streptococcus pneumoniae serotype 5 epidemic of severe pneumonia among young army recruits by mass antibiotic treatment and vaccination. Vaccine, 2010, 28, 5591-5596.	1.7	37
149	Otitis media and its consequences: beyond the earache. Lancet Infectious Diseases, The, 2010, 10, 195-203.	4.6	258
150	Appropriate Treatment of Acute Otitis Media in the Era of Antibiotic Resistance. Paediatric Drugs, 2010, 12, 3-9.	1.3	10
151	Introduction and Proliferation of Multidrugâ€ResistantStreptococcus pneumoniaeSerotype 19A Clones That Cause Acute Otitis Media in an Unvaccinated Population. Journal of Infectious Diseases, 2009, 199, 776-785.	1.9	170
152	Acute Otitis Media Caused byMoraxella catarrhalis:Epidemiologic and Clinical Characteristics. Clinical Infectious Diseases, 2009, 49, 1641-1647.	2.9	67
153	Estimation of vaccine efficacy against acquisition of pneumococcal carriage. Vaccine, 2009, 27, 3831-3837.	1.7	66
154	Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: Potential implications for pneumococcal conjugate vaccines. Vaccine, 2009, 27, 3802-3810.	1.7	107
155	New insights on pneumococcal disease: What we have learned over the past decade. Vaccine, 2009, 27, C3-C5.	1.7	16
156	Serotype replacement in perspective. Vaccine, 2009, 27, C22-C24.	1.7	72
157	Foreword. Vaccine, 2009, 27, C1-C2.	1.7	0
158	Authorsâ€™ Reply to Prymula R. Re: â€œGlobal serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: Potential implications for pneumococcal conjugate vaccinesâ€•[Vaccine 27 (2009) 4739â€“4740]. Vaccine, 2009, 27, 5429-5430.	1.7	3
159	Microbiology of the middle ear fluid in Costa Rican children between 2002 and 2007. International Journal of Pediatric Otorhinolaryngology, 2009, 73, 1407-1411.	0.4	22
160	The Effect of Universal Toddlers-Only Hepatitis A Virus Vaccination Program on Seropositivity Rate in Unvaccinated Toddlers. Pediatric Infectious Disease Journal, 2009, 28, 391-393.	1.1	18
161	Potential Contribution by Nontypable Haemophilus influenzae in Protracted and Recurrent Acute Otitis Media. Pediatric Infectious Disease Journal, 2009, 28, 466-471.	1.1	72
162	Epidemiologic and Microbiologic Characteristics of Culture-Positive Spontaneous Otorrhea in Children With Acute Otitis Media. Pediatric Infectious Disease Journal, 2009, 28, 381-384.	1.1	54

#	Article	IF	Citations
163	Clinical Outcome in Children With Culture-Negative Acute Otitis Media. Pediatric Infectious Disease Journal, 2009, 28, 1105-1110.	1.1	11
164	Serotype Coverage of Invasive and Mucosal Pneumococcal Disease in Israeli Children Younger Than 3 Years by Various Pneumococcal Conjugate Vaccines. Pediatric Infectious Disease Journal, 2009, 28, 277-282.	1.1	58
165	Introduction. Pediatric Infectious Disease Journal, 2009, 28, S63-S65.	1.1	12
166	Introduction: Childhood Respiratory Diseases. Pediatric Infectious Disease Journal, 2009, 28, S119-S120.	1.1	2
167	Pneumococcal Conjugate Vaccines Probe Studies: The Solution Points to the Problem. Advances in Experimental Medicine and Biology, 2009, 634, 69-77.	0.8	7
168	The impact of pneumococcal conjugate vaccines on otitis mediaâ€"Can we extrapolate to pneumonia?. Vaccine, 2008, 26, B16-B18.	1.7	1
169	Serotypes and pathogens in paediatric pneumonia. Vaccine, 2008, 26, B19-B23.	1.7	25
170	Comparison between two severity scoring scales commonly used in the evaluation of rotavirus gastroenteritis in children. Vaccine, 2008, 26, 5798-5801.	1.7	53
171	Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infectious Diseases, The, 2008, 8, 785-795.	4.6	213
172	Acute Otitis Media in Children. Paediatric Drugs, 2008, 10, 75-83.	1.3	42
173	Epidemiologic Evidence for Serotypeâ€Specific Acquired Immunity to Pneumococcal Carriage. Journal of Infectious Diseases, 2008, 197, 1511-1518.	1.9	117
174	Seasonality of Antibioticâ€ResistantStreptococcus pneumoniaeThat Causes Acute Otitis Media: A Clue for an Antibioticâ€Restriction Policy?. Journal of Infectious Diseases, 2008, 197, 1094-1102.	1.9	93
175	Combination vaccines containing DTPaâ€"Hib: impact of IPV and coadministration of CRM197 conjugates. Expert Review of Vaccines, 2008, 7, 97-115.	2.0	63
176	Failure to Achieve Early Bacterial Eradication Increases Clinical Failure Rate in Acute Otitis Media in Young Children. Pediatric Infectious Disease Journal, 2008, 27, 200-206.	1.1	19
177	An International Serotype 3 Clone Causing Pediatric Noninvasive Infections in Israel, Costa Rica, and Lithuania. Pediatric Infectious Disease Journal, 2008, 27, 709-712.	1.1	31
178	Universal Hepatitis A Vaccination in the United States. Pediatric Infectious Disease Journal, 2008, 27, 287-291.	1.1	9
179	The Association Between Antibiotic Use in the Community and Nasopharyngeal Carriage of Antibiotic-Resistant Streptococcus pneumoniae in Bedouin Children. Pediatric Infectious Disease Journal, 2008, 27, 776-782.	1.1	34
180	Concomitant Administration of a Virosome-Adjuvanted Hepatitis A Vaccine With Routine Childhood Vaccines at Age Twelve to Fifteen Months: A Randomized Controlled Trial. Pediatric Infectious Disease Journal, 2007, 26, 787-793.	1.1	34

#	Article	IF	Citations
181	Elimination of Hepatitis A Infection Outbreaks in Day Care and School Settings in Southern Israel After Introduction of the National Universal Toddler Hepatitis A Immunization Program. Pediatric Infectious Disease Journal, 2007, 26, 36-40.	1.1	69
182	Is Bilateral Acute Otitis Media Clinically Different Than Unilateral Acute Otitis Media?. Pediatric Infectious Disease Journal, 2007, 26, 589-592.	1.1	36
183	The use of pharmacokinetic/pharmacodynamic principles to predict clinical outcome in paediatric acute otitis media. International Journal of Antimicrobial Agents, 2007, 30, 127-130.	1.1	12
184	Site-Specific Disease Potential of Individual Streptococcus pneumoniae Serotypes in Pediatric Invasive Disease, Acute Otitis Media and Acute Conjunctivitis. Pediatric Infectious Disease Journal, 2006, 25, 602-607.	1.1	150
185	Will Reduction of Antibiotic Use Reduce Antibiotic Resistance?. Pediatric Infectious Disease Journal, 2006, 25, 981-986.	1.1	40
186	A Multicenter, Open Label, Double Tympanocentesis Study of High Dose Cefdinir in Children With Acute Otitis Media at High Risk of Persistent or Recurrent Infection. Pediatric Infectious Disease Journal, 2006, 25, 211-218.	1.1	43
187	An Open-Label, Double Tympanocentesis Study of Levofloxacin Therapy in Children With, or at High Risk for, Recurrent or Persistent Acute Otitis Media. Pediatric Infectious Disease Journal, 2006, 25, 1102-1109.	1.1	37
188	Nasopharyngeal colonization: a target for pneumococcal vaccination. Expert Review of Vaccines, 2006, 5, 651-667.	2.0	83
189	Large Dosage Amoxicillin/Clavulanate, Compared With Azithromycin, for the Treatment of Bacterial Acute Otitis Media in Children. Pediatric Infectious Disease Journal, 2005, 24, 525-532.	1.1	48
190	Community Prescribing and ResistantStreptococcus pneumoniae. Emerging Infectious Diseases, 2005, 11, 829-837.	2.0	81
191	Are Anticapsular Antibodies the Primary Mechanism of Protection against Invasive Pneumococcal Disease?. PLoS Medicine, 2005, 2, e15.	3.9	115
192	Nasopharyngeal Carriage ofStreptococcus pneumoniaeat the Completion of Successful Antibiotic Treatment of Acute Otitis Media Predisposes to Early Clinical Recurrence. Journal of Infectious Diseases, 2005, 191, 1869-1875.	1.9	23
193	Nutritional Status and Diarrheal Illness as Independent Risk Factors for Alveolar Pneumonia. American Journal of Epidemiology, 2005, 162, 999-1007.	1.6	32
194	Serum Serotypeâ€Specific Pneumococcal Anticapsular Immunoglobulin G Concentrations after Immunization with a 9â€Valent Conjugate Pneumococcal Vaccine Correlate with Nasopharyngeal Acquisition of Pneumococcus. Journal of Infectious Diseases, 2005, 192, 367-376.	1.9	146
195	Incidence of Hepatitis A in Israel Following Universal Immunization of Toddlers. JAMA - Journal of the American Medical Association, 2005, 294, 202.	3.8	216
196	Acute Otitis Media Caused by Streptococcus pyogenes in Children. Clinical Infectious Diseases, 2005, 41, 35-41.	2.9	87
197	Nosocomial bloodstream infections in children and adolescents in southern Israel: A 10-year prospective study (1992â€“2001). Scandinavian Journal of Infectious Diseases, 2005, 37, 177-183.	1.5	31
198	Immunogenicity of an inactivated hepatitis A pediatric vaccine: three-year post-booster follow-up. Vaccine, 2005, 23, 5144-5148.	1.7	12

#	Article	IF	Citations
199	Emergence of Penicillinâ€NonsusceptibleStreptococcus pneumoniaeClones Expressing Serotypes Not Present in the Antipneumococcal Conjugate Vaccine. Journal of Infectious Diseases, 2004, 190, 2154-2161.	1.9	128
200	Appropriate Use of Antibiotics: Focus on Acute Otitis Media. Clinical Pediatrics, 2004, 43, 313-321.	0.4	1
201	Reduction of Antibody Response to an 11-Valent Pneumococcal Vaccine Coadministered with a Vaccine Containing Acellular Pertussis Components. Infection and Immunity, 2004, 72, 5383-5391.	1.0	81
202	Nasopharyngeal Carriage ofStreptococcus pneumoniaeby Adults and Children in Community and Family Settings. Clinical Infectious Diseases, 2004, 38, 632-639.	2.9	239
203	Four Antibioticâ€ResistantStreptococcus pneumoniaeClones Unrelated to the Pneumococcal Conjugate Vaccine Serotypes, Including 2 New Serotypes, Causing Acute Otitis Media in Southern Israel. Journal of Infectious Diseases, 2004, 189, 385-392.	1.9	53
204	Relative Importance of Nasopharyngeal versus Oropharyngeal Sampling for Isolation of Streptococcus pneumoniae and Haemophilus influenzae from Healthy and Sick Individuals Varies with Age. Journal of Clinical Microbiology, 2004, 42, 4604-4609.	1.8	83
205	Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants. Pediatric Infectious Disease Journal, 2004, 23, 91-98.	1.1	46
206	Relationship Among Peripheral Leukocyte Counts, Etiologic Agents and Clinical Manifestations in Acute Otitis Media. Pediatric Infectious Disease Journal, 2004, 23, 406-413.	1.1	27
207	Correlation Between Bacteriologic Eradication and Clinical Cure in Acute Otitis Media. Pediatric Infectious Disease Journal, 2004, 23, 976-978.	1.1	6
208	Potential Role of Fluoroquinolone Therapy in Childhood Otitis Media. Pediatric Infectious Disease Journal, 2004, 23, 390-398.	1.1	26
209	The potential effect of widespread use of pneumococcal conjugate vaccines on the practice of pediatric otolaryngology: the case of acute otitis media. Current Opinion in Otolaryngology and Head and Neck Surgery, 2004, 12, 488-494.	0.8	37
210	The Potential of Pneumococcal Conjugate Vaccines to Reduce Antibiotic Resistance. Advances in Experimental Medicine and Biology, 2004, 549, 211-219.	0.8	2
211	Antibiotics for Acute Otitis Media in the Era of Antibiotic Resistanceâ€"What are the Choices?. Advances in Experimental Medicine and Biology, 2004, 549, 41-45.	0.8	0
212	Haemophilus influenzae: a significant pathogen in acute otitis media. Pediatric Infectious Disease Journal, 2004, 23, 1142-52.	1.1	130
213	Achieving bacterial eradication using pharmacokinetic/ pharmacodynamic principles. International Journal of Infectious Diseases, 2003, 7, S21-S26.	1.5	31
214	The potential indirect effect of conjugate pneumococcal vaccines. Vaccine, 2003, 21, 1815-1825.	1.7	143
215	Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine, 2003, 21, 3265-3272.	1.7	325
216	Independent Risk Factors for Carriage of Penicillin-non-susceptible Streptococcus pneumoniae. Scandinavian Journal of Infectious Diseases, 2003, 35, 219-222.	1.5	40

#	Article	IF	Citations
217	Vaccination of day-care center attendees reduces carriage of Streptococcus pneumoniae among their younger siblings. Pediatric Infectious Disease Journal, 2003, 22, 524-531.	1.1	88
218	Can acute otitis media caused by Haemophilus influenzae be distinguished from that caused by Streptococcus pneumoniae?. Pediatric Infectious Disease Journal, 2003, 22, 509-514.	1.1	53
219	Title is missing!. Pediatric Infectious Disease Journal, 2003, 22, 524-531.	1.1	93
220	Title is missing!. Pediatric Infectious Disease Journal, 2003, 22, 509-514.	1.1	42
221	Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers. Pediatric Infectious Disease Journal, 2003, 22, 532-539.	1.1	148
222	Bacteriologic and clinical efficacy of high dose amoxicillin for therapy of acute otitis media in children. Pediatric Infectious Disease Journal, 2003, 22, 405-412.	1.1	90
223	Bacteriologic and clinical efficacy of oral gatifloxacin for the treatment of recurrent/nonresponsive acute otitis media: an open label, noncomparative, double tympanocentesis study. Pediatric Infectious Disease Journal, 2003, 22, 943-949.	1.1	43
224	Microbiology of otitis media in Costa Rican children, 1999 through 2001. Pediatric Infectious Disease Journal, 2003, 22, 1063-1068.	1.1	53
225	Reduction of Nasopharyngeal Carriage ofStreptococcus pneumoniaeafter Administration of a 9â€Valent Pneumococcal Conjugate Vaccine to Toddlers Attending Day Care Centers. Journal of Infectious Diseases, 2002, 185, 927-936.	1.9	338
226	Acute otitis media in infants younger than two months of age: microbiology, clinical presentation and therapeutic approach. Pediatric Infectious Disease Journal, 2002, 21, 669-674.	1.1	76
227	Multinational study of pneumococcal serotypes causing acute otitis media in children. Pediatric Infectious Disease Journal, 2002, 21, 1008-1016.	1.1	114
228	Flaws in design and conduct of clinical trials in acute otitis media. Pediatric Infectious Disease Journal, 2002, 21, 894-902.	1.1	79
229	Bacterial eradication in the treatment of otitis media. Lancet Infectious Diseases, The, 2002, 2, 593-604.	4.6	61
230	Bacteriologic and clinical efficacy of trimethoprim-sulfamethoxazole for treatment of acute otitis media. Pediatric Infectious Disease Journal, 2001, 20, 260-264.	1.1	78
231	Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media. Pediatric Infectious Disease Journal, 2001, 20, 829-837.	1.1	145
232	Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees. Pediatric Infectious Disease Journal, 2001, 20, 951-958.	1.1	168
233	A Decade (1989â€“1998) of Pediatric Invasive Pneumococcal Disease in 2 Populations Residing in 1 Geographic Location: Implications for Vaccine Choice. Clinical Infectious Diseases, 2001, 33, 421-427.	2.9	80
234	Antibiotic Treatment in Acute Otitis Media Promotes Superinfection with ResistantStreptococcus pneumoniaeCarried before Initiation of Treatment. Journal of Infectious Diseases, 2001, 183, 880-886.	1.9	88

#	Article	IF	Citations
235	Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatric Infectious Disease Journal, 2000, 19, 95-104.	1.1	169
236	Development of a Chemiluminescent Optical Fiber Immunosensor to Detect Streptococcus pneumoniae Antipolysaccharide Antibodies. Applied Biochemistry and Biotechnology, 2000, 89, 117-126.	1.4	16
237	An Outbreak of Streptococcus pneumoniae Serotype 1 in a Closed Community in Southern Israel. Clinical Infectious Diseases, 2000, 30, 319-321.	2.9	87
238	Bacteriologic Efficacies of Oral Azithromycin and Oral Cefaclor in Treatment of Acute Otitis Media in Infants and Young Children. Antimicrobial Agents and Chemotherapy, 2000, 44, 43-50.	1.4	140
239	Acute Otitis Media Caused by Antibioticâ€ResistantStreptococcus pneumoniaein Southern Israel: Implication for Immunizing with Conjugate Vaccines. Journal of Infectious Diseases, 2000, 181, 1322-1329.	1.9	61
240	Treatment of acute otitis media â€" challenges in the era of antibiotic resistance. Vaccine, 2000, 19, S9-S16.	1.7	61
241	Clinical significance of antibiotic resistance in acute otitis media and implication of antibiotic treatment on carriage and spread of resistant organisms. Pediatric Infectious Disease Journal, 2000, 19, S57-S65.	1.1	73
242	Bacteriologic and clinical efficacy of one day vs. three day intramuscular ceftriaxone for treatment of nonresponsive acute otitis media in children. Pediatric Infectious Disease Journal, 2000, 19, 1040-1045.	1.1	84
243	Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatric Infectious Disease Journal, 2000, 19, 1045-1052.	1.1	134
244	Marked Differences in Pneumococcal Carriage and Resistance Patterns between Day Care Centers Located within a Small Area. Clinical Infectious Diseases, 1999, 29, 1274-1280.	2.9	70
245	Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet, The, 1999, 354, 2063-2068.	6.3	207
246	Hospitalizations for infectious diseases in Jewish and Bedouin children in southern Israel. European Journal of Epidemiology, 1998, 14, 179-186.	2.5	62
247	Prevalence of Antimicrobial-Resistant Pathogens in Middle Ear Fluid: Multinational Study of 917 Children with Acute Otitis Media. Antimicrobial Agents and Chemotherapy, 1998, 42, 589-595.	1.4	194
248	Early eradication of pathogens from middle ear fluid during antibiotic treatment of acute otitis media is associated with improved clinical outcome. Pediatric Infectious Disease Journal, 1998, 17, 776-782.	1.1	175
249	Reduced Response to Multiple Vaccines Sharing Common Protein Epitopes That Are Administered Simultaneously to Infants. Infection and Immunity, 1998, 66, 2093-2098.	1.0	210
250	Bacteriologic Response to Oral Cephalosporins: Are Established Susceptibility Breakpoints Appropriate in the Case of Acute Otitis Media?. Journal of Infectious Diseases, 1997, 176, 1253-1259.	1.9	121
251	Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens. Pediatric Infectious Disease Journal, 1997, 16, 1053-1059.	1.1	119
252	Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Pediatric Infectious Disease Journal, 1997, 16, 1060-1064.	1.1	208

#	Article	IF	Citations
253	Impaired Bacteriologic Response to Oral Cephalosporins in Acute Otitis Media Caused by Pneumococci with Intermediate Resistance to Penicillin. Pediatric Infectious Disease Journal, 1996, 15, 980-985.	1.1	166
254	Fluoroquinolones in Paediatrics - 1995. Drugs, 1995, 49, 92-99.	4.9	20
255	Hospitalization of Jewish and Bedouin infants in Southern Israel for bronchiolitis caused by respiratory syncytial virus. Pediatric Infectious Disease Journal, 1993, 12, 381-385.	1.1	58
256	Cellular Immunity and T-Lymphocyte Subsets in Young Children With Acute Measles. Journal of Medical Virology, 1987, 22, 175-182.	2.5	22
257	Nasopharyngeal Carriage. , 0, , 277-300.		3
258	Nonpolio Enteroviruses and the Febrile Infant. , 0, , 239-254.		6
259	Impact of Conjugate Pneumococcal Vaccine on Antibiotic Resistance. , 0, , 369-385.		0